TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05609201

Intervention type: DIAGNOSTIC_TEST
Intervention: HRCT Thorax
Description: HRCT Thorax at 0, 6 and 12 months

Intervention type: DEVICE
Intervention: Glycocheck Endothelial Glycocalyx Assessment
Description: Measure of EG degradation using GlycoCheck Microvascular Health Score at 0, 6 and 12 months

Intervention type: DEVICE
Intervention: Glycocheck Endothelial Glycocalyx Assessment
Description: Measure of EG degradation using GlycoCheck Microvascular Health Score at 0, 6 and 12 months

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood biomarkers
Description: Endothelial glycocalyx degradation blood biomarkers and angiogenesis markers at 0, 6 and 12 months

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood biomarkers
Description: Endothelial glycocalyx degradation blood biomarkers and angiogenesis markers at 0, 6 and 12 months

Intervention type: DIAGNOSTIC_TEST
Intervention: Peripheral leucocyte telomere length
Description: HT-STELA (High-throughput single telomere length assessment) at 0, 6 and 12 months

Intervention type: DIAGNOSTIC_TEST
Intervention: Peripheral leucocyte telomere length
Description: HT-STELA (High-throughput single telomere length assessment) at 0, 6 and 12 months

Intervention type: DIAGNOSTIC_TEST
Intervention: Pulmonary function testing
Description: Pulmonary Function Tests (Spirometry and Gas Transfer) and 6-minute walk distance at 0, 6 and 12 months

Intervention type: DIAGNOSTIC_TEST
Intervention: Patient reported outcome measures
Description: Electronic collection of patient reported outcome measures
Study: NCT05229731

Intervention type: PROCEDURE
Intervention: Neurovisual evaluation
Description: Standardized tests and scales classically used during a neurovisual evaluation,

Intervention type: PROCEDURE
Intervention: Neurovisual evaluation
Description: Standardized tests and scales classically used during a neurovisual evaluation,

Intervention type: PROCEDURE
Intervention: Cerebral MRI
Description: Sequences realized :~* 3D T1 TFE i1.0~* 3D FLAIR i1.0~* 2D T2 0.3 coro, centré sur les orbites~* 3D T2 i0.6~* SWIp 0.6~* 3D PD T2 NO, centré sur les orbites~* 3D ASL~* DTI 64dir

Intervention type: PROCEDURE
Intervention: Cerebral MRI
Description: Sequences realized :~* 3D T1 TFE i1.0~* 3D FLAIR i1.0~* 2D T2 0.3 coro, centré sur les orbites~* 3D T2 i0.6~* SWIp 0.6~* 3D PD T2 NO, centré sur les orbites~* 3D ASL~* DTI 64dir
Study: NCT05493241

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation for Independence in Older Veterans (ACTIVaTE)
Description: 6 sessions delivered by a psychology trainee by telehealth will cover the core content of an existing BA model, Brief Behavioral Activation for Depression-Revised (BATD-R), including education on BA and rationale for the intervention, activity monitoring, values exploration, and activity selection and planning. ACTIVaTE will include the following key modifications: 1) modifying background and psychoeducation to focus on maintaining functional independence; 2) tailoring content to Veterans; 3) adapting materials for VVC telehealth delivery; 4) incorporating elements of activity and environmental modification from an OT perspective; and 5) adding content on VA and community resources for older Veterans. Each session is structured similarly, consisting of education or review of concepts, review of homework and troubleshooting challenges, discussion of core content (e.g. values exploration or activity planning/scheduling), and assignment of homework for the next session.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Behavioral Activation for Independence in Older Veterans (ACTIVaTE)
Description: 6 sessions delivered by a psychology trainee by telehealth will cover the core content of an existing BA model, Brief Behavioral Activation for Depression-Revised (BATD-R), including education on BA and rationale for the intervention, activity monitoring, values exploration, and activity selection and planning. ACTIVaTE will include the following key modifications: 1) modifying background and psychoeducation to focus on maintaining functional independence; 2) tailoring content to Veterans; 3) adapting materials for VVC telehealth delivery; 4) incorporating elements of activity and environmental modification from an OT perspective; and 5) adding content on VA and community resources for older Veterans. Each session is structured similarly, consisting of education or review of concepts, review of homework and troubleshooting challenges, discussion of core content (e.g. values exploration or activity planning/scheduling), and assignment of homework for the next session.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention control
Description: An attention control (AC) group will be used to control for the social interaction and educational aspects of ACTIVaTE. The AC arm will consist of 6 weekly one-hour VVC-delivered sessions including friendly social conversation plus education on remaining active within the physical, cognitive, and social domains during older adulthood. During each session, the interventionist will review a relevant handout or other educational materials with the participant. AC interventionists will not be trained in the ACTIVaTE intervention, and the investigators will assess whether any key features of ACTIVaTE (activity monitoring/planning, values exploration, problem-solving) are incidentally incorporated into this arm during fidelity assessment.
Study: NCT05344729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB3616 Capsule
Description: It inhibits the proliferation of tumor cells by reducing the level of retinoblastoma protein (Rb) phosphorylation in cancer cells and blocking the progression of cells from G1 to S phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB3616 Capsule
Description: It inhibits the proliferation of tumor cells by reducing the level of retinoblastoma protein (Rb) phosphorylation in cancer cells and blocking the progression of cells from G1 to S phase.
Study: NCT05444049

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NEURESCUE device
Description: The balloon catheter is delivered via the femoral artery, temporarily inflating a soft balloon in the descending aorta to redirect blood flow towards the upper body.
Study: NCT06608173

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: radKIDS2.0 Safety and Empowerment Education Program
Description: radKIDS® uses activity-based skill training to help elementary aged children develop personal safety boundaries, critical thinking skills for responding to threats of danger, age-appropriate coping strategies for dealing with current and past victimization, self-assertiveness and physical skills for self-defense, communication skills for reporting incidences to parents/adults, and increasing child self-worth-the program's cornerstone for personal safety and healthy development for elementary students.
Study: NCT05396677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: 2 x 500 mg acetaminophen (one time)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 x 500 mg microcrystalline cellulose (one time)
Study: NCT05134441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMU-838 tablets
Description: Patients are randomized to IMU-838 or placebo in ratio 1:1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching IMU-838 tablets
Description: Patients are randomized to IMU-838 or placebo in ratio 1:1
Study: NCT05441709

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Ci-BPC with Standard of Care (SOC)
Description: Clinically-integrated breastfeeding peer counseling (ci-BPC) is a practice that, supports the patient and the clinical care team by delivering culturally-appropriate breastfeeding help to motivate breastfeeding initiation, intensity, and duration, inspiring confidence for patients to set breastfeeding goals and meet them. ci-BPC is delivered by community health workers who have breastfed an infant, and have received basic training in breastfeeding support through a qualified BPC training organization. For this project, the Peer Counselor will make initial contact to patients randomized into the treatment arm via phone to schedule the Intake Encounter between 20 and 30 weeks gestation. Subsequently, each patient will receive a minimum of 3 additional encounters which can occur virtually or in-person. Patients randomized to the ci-BPC arm are additionally offered access to a warmline where messages will be returned by the next business day.
Study: NCT04729998

Intervention type: DRUG
Group type: OTHER
Intervention: Rivaroxaban film-coated tablet 20 mg
Description: Rivaroxaban is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 20 mg of rivaroxaban.

Intervention type: DRUG
Group type: OTHER
Intervention: Rivaroxaban film-coated tablet 20 mg
Description: Rivaroxaban is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 20 mg of rivaroxaban.

Intervention type: DRUG
Group type: OTHER
Intervention: Xarelto® film-coated tablet 20 mg
Description: Xarelto® is manufactured by Bayer AG, Germany. Each tablet contains 20 mg of rivaroxaban.

Intervention type: DRUG
Group type: OTHER
Intervention: Xarelto® film-coated tablet 20 mg
Description: Xarelto® is manufactured by Bayer AG, Germany. Each tablet contains 20 mg of rivaroxaban.
Study: NCT06337526

Intervention type: DEVICE
Intervention: Apple Watch v8
Description: Apple Watch used for data collection only
Study: NCT05219474

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cochlear implant Computer Model Implementation
Description: The computer model will use standard Cochlear Implant settings to evaluate psychophysical and speech understanding abilities and sound quality with standard CI settings and then use these measures to build subject-specific models and determine experimental active electrode conditions to be tested: model-optimized, and two best-electrodes settings (2 types); 3) evaluate speech understanding and sound quality measures after using experimental settings regularly for 1.5 months; and 4) compare performance across experimental and clinical conditions.~The analysis will include four levels of repeated measures with active CI electrode conditions. These levels include the clinical baseline condition (all available electrodes active) and three experimental conditions (model-optimized, best-electrodes, and restricted best-electrodes).
Study: NCT04970030

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ML lithotripsy
Description: we will proceed under fluoroscopic vision with TTS mechanical lithotripter (Trapezoid, RX Wireguided Retrieval Basket, Boston Scientific) with mechanical fragmentation of the stone and subsequent complete cleaning of the biliary tract using the fluoroscopic technique.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EHL lithotripsy
Description: after administration of IV antibiotic therapy, we will proceed to cholangioscopy with SpyGlass ™ DS (Boston Scientific Corporation, USA), treatment of difficult biliary lithiasis with electrohydraulic lithotripsy with Autolith probe (Northgate Technologies Inc USA) and subsequent complete cleaning of the biliary tract using the fluoroscopic technique
Study: NCT04889547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Intraoperative intravenous dexamethasone

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No dexamethasone
Description: No intraoperative intravenous dexamethasone
Study: NCT05938374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib
Description: One week before RT onset, during radiotherapy and 5 weeks post-RT, patients also take oral Fluzoparib (100mg, BID, five days per week).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Preoperative moderately fractionated radiotherapay
Description: Patients will receive preoperative moderately fractionated radiotherapy (RT)(43.5Gy/15fr).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Preoperative moderately fractionated radiotherapay
Description: Patients will receive preoperative moderately fractionated radiotherapy (RT)(43.5Gy/15fr).
Study: NCT05974215

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: assessment of change in bone height by cone beam computed tomography
Description: bone height was measured at 1 ,30 ,90 days after denture insertion

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: assessment of change in bone height by cone beam computed tomography
Description: bone height was measured at 1 ,30 ,90 days after denture insertion
Study: NCT05272956

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: enteral feeding with pushed syringe by the parents
Description: enteral feeding pushed by parents with a syringe
Study: NCT06007950

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time-restricted eating 10-hr
Description: Time-restricted eating is a form of intermittent fasting. In this study, 10-hr TRE will be employed, where eating duration is limited to 10 hours. Participants are allowed to consume non-caloric beverages during fasting period.
Study: NCT06107608

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FAPI PET/CT
Description: The radiopharmaceutical 68Gallium-FAPI-46 (FAPI) is injected intravenously for molecular imaging of FAP expression with FAPI PET/CT.
Study: NCT06101849

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: I-Can-Manage-Pain after cancer (Pain Management Program)
Description: 6-week online interprofessional cancer pain management program (I-Can-Manage-Pain after cancer) for survivors of breast cancer. The program will cover the topics of understanding cancer pain, exercises to manage pain and psychological strategies to cope with pain
Study: NCT06108882

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Manual Ischemic Compression with Strain Counter Strain technique
Description: The duration of intervention will be 6 weeks, 3 sessions a week, a total of 18 sessions will be given to the study participants. Each session will last for 30 to 45 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Manual Ischemic Compression
Description: The duration of intervention will be 6 weeks, 3 sessions a week, a total of 18 sessions will be given to the study participants. Each session will last for 30 to 45 minutes.
Study: NCT05374161

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: The ACT-based intervention will be delivered in a group format. Due to the COVID-19 pandemic and given that breast cancer patients are considered a vulnerable population, the intervention will be administered online through a GDPR compliant platform. The six, weekly, 90-minute treatment sessions (total of 9 hours) will be conducted in groups of approximately 8-10 participants and one therapist.

Intervention type: OTHER
Group type: OTHER
Intervention: Waitlist Control Group
Description: Participants randomized to the WL condition will be asked to continue receiving the services they receive from anti-cancer associations (receiving care from nurses, or/and support from social workers, or/and physiotherapy or/and individual psychological support from licensed psychologists just like the women in the experimental condition).
Study: NCT05657717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Manukamed - Manukapli 100% sterile honey wound dressing - Premium medical grade 16+ Leptospermum Scoparium New Zealand honey
Description: After surgical reconstruction of the tympanic membrane by grafting, Manukamed - Manukapli 100% Sterile honey wound dressing is applied onto the gelfoam to close the area, followed by an antibiotic tampon.
Study: NCT04999098

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Echinaforce Forte tablets
Description: Tincture of fresh Echinacea purpurea (L) MOENCH: Herba rec. T. aerial part DER = 1:12-13 (Drug to extraction solvent ratio) extraction solvent = ethanol 65.1 % (V/V) = 57.3 % (m/m)\* with an approx. dry plant equivalent of 32 mg per tablet Dry weight content in 1 tablet: 5.9 mg~Echinacea purpurea: (L) MOENCH: Radix rec. root part DER = 1:11-12 (Drug to extraction solvent ratio) extraction solvent = ethanol 65.1 % (V/V) = 57.3 % (m/m)\* with an approx. dry plant equivalent of 1.8 mg per tablet Dry weight content in1 tablet: 0.3 mg~the tablet contain additional excipients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Echinaforce Chewable tablets
Description: Tincture of fresh Echinacea purpurea (L) MOENCH: Herba rec. T. aerial part DER = 1:12-13 (Drug to extraction solvent ratio) extraction solvent = ethanol 65.1 % (V/V) = 57.3 % (m/m)\* with an approx. dry plant equivalent of 32 mg per tablet Dry weight content in 1 tablet: 5.9 mg~Echinacea purpurea: (L) MOENCH: Radix rec. root part DER = 1:11-12 (Drug to extraction solvent ratio) extraction solvent = ethanol 65.1 % (V/V) = 57.3 % (m/m)\* with an approx. dry plant equivalent of 1.8 mg per tablet Dry weight content in1 tablet: 0.3 mg~The tablets contain additional excipients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Echinaforce tincture
Description: Tincture of fresh Echinacea purpurea (L) MOENCH: Herba rec. T. aerial part DER = 1:12-13 (Drug to extraction solvent ratio) extraction solvent = ethanol 65.1 % (V/V) = 57.3 % (m/m)~Echinacea purpurea: (L) MOENCH: Radix rec. root part DER = 1:11-12 (Drug to extraction solvent ratio) extraction solvent = ethanol 65.1 % (V/V) = 57.3 % (m/m)
Study: NCT05624320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-190584
Description: miotic for treatment of presbyopia
Study: NCT05507905

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Music
Description: Music associated with dance forms in dance classes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dance Classes
Description: Four Different dance forms taught for 6 weeks each

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dance Classes
Description: Four Different dance forms taught for 6 weeks each

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dance Classes
Description: Four Different dance forms taught for 6 weeks each
Study: NCT05302388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SIBP-R002
Description: SIBP-R002: injection; strength: 1, 2, 4, 8 or 12 mg; dose escalation and the first group is 1mg (intravenous infusion, 5 groups, the first group consisted of four people, and the other groups consisted of eight).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone or Methyl prednisolone
Description: Intravenous infusion, 5mg or 1\~2mg/kg. These were administered within 30 minutes prior to infusion of the experimental drug.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone or Methyl prednisolone
Description: Intravenous infusion, 5mg or 1\~2mg/kg. These were administered within 30 minutes prior to infusion of the experimental drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: 10mg, intramuscular injection.These were administered within 30 minutes prior to infusion of the experimental drug.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Diphenhydramine
Description: 10mg, intramuscular injection.These were administered within 30 minutes prior to infusion of the experimental drug.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The same volume of placebo as SIBP-R002: injection; strength: the same volume of placebo as SIBP-R002 of 1, 2, 4, 8 or 12 mg (intravenous infusion, 5 groups, the first group consisted of one people, and the other groups consisted of two). The rule and dose of placebo were the same as SIBP-R002.
Study: NCT05837715

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chattanooga Stabilizer pressure biofeedback
Description: Stabilization exercises, which form the basis of spinal stabilization training, increase the strength and endurance of the postural and stabilizer muscles by using the basic principles of motor learning, and improve balance control in stable and unstable positions.~In addition, stabilization exercises include kinesthetic training and functional training.~Spinal stabilization training is very important for proper control of extremity movements.~It is also an important factor in the formation of proper spinal posture and the neutral position required for the spine.~In cervical region problems, cervical stabilization exercises that activate the deep neck flexors (longus colli and longus capitis) can be applied.~Cervical stabilization training improves the cervical proprioception sense as well as strength and endurance, thereby reducing joint position sense error.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VibraSens - Focal Vibration Therapy (TechnoConcept - France)
Description: Vibration applications have also started to be used for treatment purposes. Therapeutic vibration produces minor changes in skeletal muscle length. Vibrations elicit a response called the tonic vibration reflex, which includes activation of muscle spindles, neural signals by Ia afferents, and activation of muscle fibers via large α-motor neurons. The tonic vibration reflex can also cause an increase in activation of motor units through activation of muscle spindles and polysynaptic pathways. It is well known that the input of the proprioceptive pathways (Ia, IIa and possibly IIb) plays an important role in the production of isometric contractions. The increase in isometric strength after application of vibration with extensive sensory stimulation may be the result of more efficient use of the positive proprioceptive feedback loop. It can be predicted that the increased muscle strength after vibration application is due to neural adaptation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: Telerehabilitation is a method that aims to provide rehabilitation to patients/clinicians by reducing obstacles such as distance, time and cost by using information and communication technologies. Telerehabilitation enables patients who cannot access rehabilitation due to geographic, economic or physical disabilities to benefit from rehabilitation services. The COVID-19 pandemic has highlighted the importance of telerehabilitation practices. In order to minimize the risk of transmission in the COVID-19 pandemic, the physical activity levels of individuals have decreased and their access to rehabilitation services has been restricted by the restriction of social life.
Study: NCT05745831

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic decision tool
Description: A therapeutic decision tool will be used and its usefulness, comprehension and satisfaction will be evaluated
Study: NCT05039528

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized OSA messages
Description: Participants will receive personalized OSA messages designed to nudge and navigate them toward evaluation and treatment for OSA. Participants will complete questionnaires at baseline and at study follow-up.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Participants will complete questionnaires at baseline and at study follow-up. At the end of the study period, participants will receive the OSA message intervention.